Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
AQST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $5.80
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.31M
Market Cap
$283.76M
Enterprise Value$375.06M
Total Cash (Recent Filing)-$9.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 06, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding98,871,370
10 Day Avg. Volume1,097,255
30 Day Avg. Volume1,307,545
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.51
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.45
Enterprise Value/Ebitda-13.39
Forecast
1Y Price Target
$8.15Price Target Upside183.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Aquestive Therapeutics News
PremiumCompany Announcements
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA
PremiumCompany Announcements
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Aquestive Therapeutics Advances Product Pipeline and Market Access---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe NDA is supported by results from the Phase 3 pivotal trial where Anaphylm demonstrated rapid onset of action with exposure levels comparable to auto-injectors.
Market PotentialThe T1A market should be large enough for multiple no-needle epi players including Anaphylm, and no-needle epi products should ultimately 'grow the pie' & drive meaningful expansion of the T1A market beyond current autoinjectors longer-term.
Regulatory ProgressFDA acceptance of the Anaphylm NDA submission is expected, and the advisory committee meeting process could highlight the potential benefits of Anaphylm for patients.
Bears Say
Financial ConcernsAquestive ended with approximately $93M in cash and cash equivalents, which management expects should provide financial runway into 2026.
Regulatory DelaysAnaphylm NDA submitted, setting up potential approval in early 2026.
---
Ownership Overview
13.55% Insiders
6.68% Mutual Funds
0.24% Other Institutional Investors
72.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.20 and its highest was $5.80 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $283.76M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 9 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Mar 05, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.133 by -$0.057.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 98,871,370 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.133. Following the earnings report the stock price went down -7.527%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
---
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.15 (183.97% Upside)
$8.15 (183.97% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 449.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $213.8 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.97%
12-Months-Change
Fundamentals
Return on Equity
77.48%
Trailing 12-Months
Asset Growth
76.64%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products that address unmet medical needs. The company specializes in orally administered drug delivery systems, leveraging its proprietary PharmFilm technology to create novel dosage forms. Aquestive's core products primarily target central nervous system (CNS) conditions, including epilepsy and anxiety disorders, offering patients alternative administration routes that improve convenience and compliance.
---
AQST Company Deck
---
AQST Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Aquestive Therapeutics demonstrated significant progress in advancing its lead asset Anaphylm towards FDA approval and preparing for international expansion. However, challenges include decreased quarterly revenue, increased net loss, and legal setbacks for Libervant. The sentiment is mixed with balanced highlights and lowlights.Read More>---
AQST Stock 12 Month Forecast
Average Price Target
$8.15
▲(183.97% Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Rockwell Med
―
Esperion
―
Journey Medical Corp
―
Best Analysts Covering AQST
1 Year
1 Year Success Rate
17/36 ratings generated profit
1 Year Average Return
+37.96%
reiterated a buy rating 27 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 47.22% of your transactions generating a profit, with an average return of +37.96% per trade.
---